期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

胃癌组织Her-2/neu与TopoⅡα的表达及临床意义 被引量：2

Expression and clinical significance of Her-2/neu、TopoⅡα in gastric carcinoma
下载PDF
导出
摘要 目的:探讨Her-2/neu、TopoⅡα在胃癌组织中的表达及临床意义。方法:应用免疫组织化学PV-9000方法检测90例胃癌及30例正常胃组织中Her-2/neu、TopoⅡα的表达情况,分析二者的表达与临床病理特征之间的关系。结果:90例胃癌组织和30例正常胃组织中Her-2/neu阳性表达率分别为20.0%和3.3%(P<0.05),TopoⅡα阳性表达率分别为65.6%、86.7%(P<0.05)。胃癌组织Her-2/neu的过表达与胃癌的Lauren分型、分化程度、淋巴转移显著相关。胃癌组织中TopoⅡα阳性表达仅与肿瘤的分化程度相关。在18例Her-2/neu高表达的胃癌中有72.2%(13/18)伴有TopoⅡα的表达,在77例TopoⅡα阳性表达的组织中有16.9%(13/77)伴有Her-2/neu的过表达。结论:Her-2/neu、TopoⅡα在胃癌组织表达增高与胃癌的发生发展密切相关,联合检测Her-2/neu、TopoⅡα对于胃癌的治疗具有指导意义,也是判断预后的重要指标。 Objective：To study the expression and clinical significance of Her -2/neu, TopoⅡα in gastric carcinoma tissue. Methods： The expressions of Her - 2/neu and TopoⅡα were detected by PV - 9000 immunohistochemical technique in 90 cases of gastric carcinoma and 30 cases of gastric normal tissue and analyze the relationship between the expression of Her- 2/neu, TopoⅡα and the clinical prognosis of patients. Results： The overexpression incidence of Her -2/neu in 90 cases of gastric cancer and in 30 cases of normal gastric tissue were respectively 20.0% ,3.3% （P 〈 0.05 ） ,and TopoⅡα were respectively 65.6% , 86.7% （P 〈 0.05 ）. Overexpression of Her- 2/neu was significandy correlated to Lauren type, degree of differentiation, lymph node metastasis. The expression of TopolIot only had a closely relationship with the degree of differentiation. 72.2% （13/18） of Her -2/neu amplification had coneomitant TopoⅡα amplication. Conclusion： The overexpression of Her -2/neu and TopoⅡα may play a role in the pathogenesis of gastric carcinoma, combined detection would be of benefit in selecting chemotherapeutic agents and evaluating prognosis in gastric carcinoma.
作者 马钊 武华 赵浩亮 鲍民生
机构地区 山西医科大学第一附属医院普外科
出处 《现代肿瘤医学》 CAS 2008年第10期1716-1718,共3页 Journal of Modern Oncology
关键词 胃癌 人类表皮生长因子2 拓扑异构酶Ⅱα gastric carcinoma Her - 2/neu TopoⅡα
分类号 R735.2 [医药卫生—肿瘤]
  • 相关文献

参考文献2

二级参考文献24

  • 1Mano MS,Awada A,DiLeo A,et al.Rtes of topomerase Topo Ⅱ -alpha and HER2 gene amplification and expression in epithelial ovarian carcinoma[J].Gynecologic Oncology,2004,92(6):887-895.
  • 2Tanner B,Pilch H,Schaffer U,et al.Expression of c-erbB-2 and Topoisomerase Ⅱ alpha in relation to chemoresistance in ovarian cancer[J].Zentralbl Gynakol,2002,124(3):176-183.
  • 3von Minckwitz G,Harder S,Hovelmann S,et al.Phase 1 clinical study of the recombinant antibody toxin ScFv(FRP5)-ETA specific for the ErbB2/HER2 receptor in patient with advanced solid malignomas[J].Breast Cancer Res,2005,7(5):617-626.
  • 4Liu S,Liu W,Jakubczak JL,et al.Genetic instability favoring transversions associated with ErbB2-indueed mammary tumorigenesis[ J ].Proc Natl Acad Sci USA,2002,99(6):3770-3775.
  • 5Bradt-Rauf PW,Rackovsky S,Pincus MR.Correlation of the neu structure of the transmembrans domain of the neu oncogene-encoded p185 protein with its function[ J ].Proc Natl Acad Sci USA,1990,87 (21):8660 -8664.
  • 6Fei R,Shaoyang L.Combination antigene therapy targeting c-myc and cerbB-2in the ovary cancer cos(1) cell line[ J ].Gynecol Oncol,2002,85(1):40-44.
  • 7rban-Klein B,Werth S,Abuharbeid S,et al.RNAi-mediated gene-targeting through systemic application of polyethylenimine (PEI)-complexed siRNA in vivo[J].Gene Ther,2005,12(5):461-466.
  • 8Bhat UG,Raychaudhuri P,Beck WT.Functional interaction between human topoisomerase and retinoblastoma protein[ J ].Proc Natl Acad Sci USA,1999,96(14):7859-7864.
  • 9Sandri MI,Isaacs RJ,Ongkeko WM,et al.p53 regulates the minimal promoter of the human topoisomerase Ⅱ[ alpha] gene[ J ].Nucletic Acids Res,1996,24(22):4464-4470.
  • 10Jenkins JR,Ayton P,Jones T,et al.Isolation of cDNA clones encoding the beta isozyme of human DNA topoisomerase Ⅱ and localisation of the gene to chromosome 3p24[J].Nucleic Acid Research,1992,20(21):5587-5592.

共引文献22

同被引文献10

  • 1赵淑萍,王泽华.卵巢癌化疗耐药基因检测的研究进展[J].国外医学（妇产科学分册）,2006,33(1):57-60. 被引量：2
  • 2Schintt SJ. Breast cancer in 21st century neu opportunities and neu challenge[J] . Mod Pathol,2001,14(3) : 133-146 .
  • 3Gotlieb WH, Goldberg I, Weise B, et al. Topoisomerase Ⅱ immunostaining as a prognostic marker for survial in ovarian cancer[J]. Gynecol Oncol ,2001, 82( 1 ) :99-104.
  • 4Provencio M, Corbaeho C, Salas C, et al. The topoisomerase llal- pha expressioneorrelates with survival in patients with advanced Hodgkin's lymphoma [ J]. Clin Cancer Res, 2003, 9 (4):1406- 1411.
  • 5Brustmarm H. Expression of cellular apoptosis susceptibility protein in serous ovarian carcinoma: a clinicopathologic and immunohistochemical study[J]. Gynecol Oncol, 2004 ,92( 1 ) : 258-275.
  • 6Provencio M, Corbacho C, Salas C ,et al. The topoisomerase Ilalpha expression correlates with survival in patients with advanced Hodgkin's lymphoma [J]. Clin Cancer Res, 2003,9 (4):1406-1411.
  • 7Brustmann H. Expression of cellular apoptosis susceptibility protein in serous ovarian carcinoma : a clinicopathologic and immunohistochemical study [ J ]. Gynecol Oncol,2004,92 (1) :268-276.
  • 8Lehnert M. Clinical multidrug resistance in cancer: a multifactorial problem [J]. Eur J Cancer, 1996,32A(6) :912-920.
  • 9Mano MS, Awada A, Di Leo A, et al. Rates of topoisomcrase Ⅱ-alpha and HER-2 gene amplification and expression in epithelial ovarian carcinoma [ J ]. Gynecol Oncol, 2004,92 ( 3 ) : 887-895.
  • 10王克芳,王险峰.Her-2基因表达下调后卵巢癌细胞对化疗敏感性的改变[J].中国医药,2010,5(2):97-99. 被引量：1

引证文献2

二级引证文献3

现代肿瘤医学
2008年 第10期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部